Pharmaceutical firm recruits industry ‘big hitters’ to help steer its international growth journey

A number of industry veterans have arrived at the Hampshire headquarters of TMC Pharma Services off the back of major international growth for the firm.

TMC supports pharma and biotech companies in their work developing treatments for rare diseases and cancers, with most of their clients based in the EU, North America and Asia.

Hoping to build on this support is Stewart Sharpe, pictured left, who joins the firm as CCO to oversee its operations and strategic relationships both within the UK and overseas.

Up to now, Stewart has led a successful career building teams and launching pharma brands across the world, most recently serving as VP global commercial lead for Syneos Health.

Alongside him comes Rondeep Bhui, transferring from his role as head of global pharmacovigilance at Boehringer Ingelheim’s Vetmedica wing to now serve as head of strategic planning at TMC.

Rondeep offers plenty of experience in both human and veterinary medicines and across the fields of pharmacovigilance, regulatory and clinical research.

Also joining TMC are Dr Victoria Datsenko as VP clinical services and Dr Marcelo Vaz as head of medical services.

Victoria has been working in global clinical research for more than 20 years with a focus on oncology, cell, and gene therapy, while Marcelo previously led the Biotech unit at ICON plc and specialises in a range of respiratory diseases.

CEO Julie Matthews, pictured right, said: “We’re thrilled to be welcoming so many experienced and well-respected healthcare professionals to our team.

“They each have wide-ranging experience of growing businesses on an international scale and, as we continue to pursue expansion in the USA, Asia and other key global territories, they will be a huge asset in helping us to achieve our goals.

“Our strong growth over the last year has meant we’re well positioned to attract exceptional industry talent, and I believe we’ve built the perfect platform to accelerate our international growth as a result.”

The news follows last year’s £18 million minority investment from private equity firm LDC, since which TMC has boosted its staff numbers by more than 20 per cent.

One of these many hires was biotech veteran Gordon Cameron, who became non-executive director at the company in October 2022.

Stefan Gunn, Investment Director at LDC, added: “The global pharmaceutical market continues to evolve and flourish.

“This means there’s considerable demand for highly qualified people who have the right combination of industry experience and commercial insight to help businesses achieve their objectives.

“With this latest series of senior appointments, TMC has secured a number of big hitters from the industry and their combined experience will bring additional expertise to support TMC’s global customer base as the company continues its growth journey.”